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Roughly  ten  years  ago  the FDA  approved  most  of  the  presently  used  anti-VEGF  drugs  for  the  treatment
of  neovascular  AMD  and other  eye  pathologies  characterized  by  ocular  neoangiogenesis.  However,  the
recent  ﬁndings  on  the physiologic  activities  of  VEGF  isoforms  impose  to reconsider  the  inhibitory  effects
of  pan-VEGF  antagonists  and  the concept  that  to face  pathological  alterations  at  ocular  level  is  possible
only  through  the  full  block  of  all  VEGF  isoforms.  In  fact,  although  pan-VEGF  agents  rapidly  and  effectively
contrast  ocular  neovascularization,  vascular  leakage,  and  other  pathological  changes,  in  the  long-term
the  inhibition  of  all VEGF  isoforms  likely  may  result  in the  loss  of  the  physiologic  effects  exerted  by
VEGF121 and the  anti-angiogenic  VEGF165b. Notably,  selective  inhibitors  of  VEGF165a, such as  pegaptanib,
spare these  targets.  Moreover,  preclinical  and  clinical  evidence  suggests  that also  systemic  side  effects,
secondary  to  intraocular  treatment  with  non-selective  anti-VEGF  drugs,  may  be  reinterpreted  in light  of
these  recent  ﬁndings,  which  may  be useful  to  clinicians  for the  choice  of  the most  appropriate  anti-VEGF
agent.
Another  aspect  that  should  be considered  is  the  involvement  of VEGF-independent  pathways  in ocu-
lar  neovascularization,  therefore  a combined  therapy  can  represent  a  more  effective  pharmacological
approach  that might  help  also  to  counteract  tachyphylaxis,  an important  issue  in anti-VEGF  treatment.This  complex  picture  and  the recent  ﬁndings  on current  anti-VEGF  drugs  should  be therefore  taken  into
account  to guide  the  development  of  novel  agents  targeting  VEGF  and/or  other key  factors  involved  in  the
pathogenesis  of  neovascular  ocular  diseases  along  the signaling  pathways  stimulated  by  the  various  iso-
forms.  Accordingly,  this  review  also  reports  on novel  pharmacological  molecules  targeting  VEGF  at  ocular
level  and  currently  under  development,  with  a special  attention  to  oligonucleotide-based  interventions.
© 2015  The  Authors.  Published  by  Elsevier  Ltd.  This  is  an  open  access  article  under the  CC  BY license
(http://creativecommons.org/licenses/by/4.0/).
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. Ocular angiogenesis as a major cause of visual
mpairment
Age-related macular degeneration (AMD) and diabetic retinopa-
hy (DR) are the most common ocular diseases dramatically
ffecting the quality of life of patients and causing an enormous bur-
en to the healthcare system in Europe and USA [1,2]. AMD, whose
athogenesis is multifactorial and not yet fully elucidated, is clas-
iﬁed in early and late stages, atrophic dry (85%) and exudative wet
eovascular (15%) degeneration categories [3]. Quite similarly, DR,
 sight-threating complication of diabetes developed by more than
ne-third of diabetic individuals, is classiﬁed in two stages: non
roliferative and proliferative [4,5]. In some cases, both non pro-
iferative AMD  and DR may  progress and convert to proliferative
eovascular forms, in which the formation of new vessels from the
xisting ones, a process named “ocular angiogenesis”, represents a
ajor cause of visual loss. Neovascular AMD  and DR are the leading
auses of blindness in elderly and working age people, respectively
6,7]. These pathologies are associated with neovascularization in
he posterior segment of the eye; in particular, the hallmark of
et AMD  is the formation of new blood vessels arising from the
horoidal microvascular bed and invading the sub-retinal space,
hile DR presents alterations preferentially at retinal level [8,9].
lthough with some differences, both neovascular AMD  and DR are
haracterized by endothelial cell (EC) proliferation and migration,
ncrease in vascular permeability and inﬂammation, all processes in
hich Vascular Endothelial Growth Factor-A (VEGF-A) plays a key
ole. In mammals, VEGF-A belongs to a family that also includes
EGF-B, -C, -D, and placental growth factor (PLGF). Among these
losely-related growth factors, VEGF-A is the most potent media-
or of both retinal and choroidal angiogenesis, and its inhibition via
ntraocular anti-VEGF treatments currently represents the corner-
tone of therapies for both AMD  and DR [10,11]. The outcomes of
nti-VEGF treatments are to counteract pathological neovascular-
zation and disease progression, to arrest visual impairment and, in
he best case, to gain the recovery of vision. Some molecules tar-
eting VEGF-A pathway and acting at multiple levels are currently
sed in ophthalmology, and much more are under investigation in
linical trials for either AMD, DR, or other eye diseases character-
zed by neovascularization [12,13]. These anti-VEGF-A drugs can
e divided in three main pharmacological classes: (1) molecules
argeting VEGF isoforms, (2) molecules inhibiting VEGF receptors,
nd (3) molecules inhibiting VEGF downstream signaling [14]. This
eview will focus on current therapies and novel substances under
evelopment belonging to the ﬁrst pharmacological class, with a .  . .  . . . .  . . .  . . . . .  .  . . . . .  . .  .  .  . . .  . . .  . . . . . . .  .  . . .  .  . . . .  .  .  . . . . .  . . . . . . .  .  .  .  . . .  .  . .  . . . .  .  264
special attention to oligonucleotide-based interventions targeting
VEGF at ocular level.
2. Pharmacodynamic classiﬁcation and clinical application
of drugs acting upon VEGF
Several agents have been developed to interfere with the VEGF
system and various molecules are already used especially in cancer
therapy. A few of them are approved as ophthalmic therapies, such
as ranibizumab (Novartis), pegaptanib (Bausch & Lomb) and aﬂiber-
cept (Bayer), others are under investigation and/or currently used
off-label like bevacizumab (Roche). They mainly act on VEGF itself
or on its gene expression and comprise some promising molecules
under preclinical or clinical investigation, that will be brieﬂy illus-
trated later on in this review.
A fundamental class of therapeutics acting as angiogenesis
inhibitors is represented by monoclonal antibodies characterized
by a high speciﬁcity for a given target, which they bind and neu-
tralize. In this category, ranibizumab is an engineered recombinant
humanized Fab fragment of 48 kDa designed from the full-length
monoclonal antibody bevacizumab to optimize retinal penetration.
Ranibizumab binds with high afﬁnity a site present in all VEGF-A
isoforms (see below) and their bioactive proteolytic fragments [15].
On the market since 2006, ranibizumab is approved by FDA for the
treatment of all lesion types in neovascular AMD, diabetic macular
edema (DME), and macular edema secondary to retinal vein occlu-
sion (RVO) [16]. Its intraocular administration is recommended at a
dosage of 0.5 mg/month, and treatment protocols usually advice an
initial loading dose of three monthly injections followed by admin-
istration pro re nata (PRN) based on the disease activity. However,
as for the other anti-VEGF treatments, the optimal regimen has
yet to be established, although recently the ophthalmic commu-
nity has made available guidelines on the treatment of patients
with advanced AMD  also to help clinicians to prevent over- and/or
under-treatment with anti-VEGF therapy [11,17].
Bevacizumab is a full-length humanized monoclonal IgG anti-
body of 149 kDa targeting the same site of ranibizumab, and thus
inhibiting all VEGF-A isoforms. Approved in 2004 by FDA for sys-
temic use in the treatment of certain metastatic cancers, it is
widely used off-label as intravitreal therapy in proliferative eye
diseases, especially neovascular AMD  and DME, although with vari-
ous limitations of medical, ﬁnancial and ethical nature [18–20]. The
recommended dose for intraocular treatment is 1.25 mg/month.
Aﬂibercept, or VEGF Trap-Eye, is a fully human recombinant
protein of 115 kDa consisting of key binding domains from VEGF
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eceptor (VEGFR)-1 and VEGFR-2 fused to an IgG Fc fragment [21].
t acts as a soluble decoy receptor recognizing and neutralizing all
EGF-A isoforms, with the establishment of a tighter binding than
he native receptors. Unlike the anti-VEGF monoclonal antibodies
urrently in use, aﬂibercept is purposely designed to inhibit also
EGF-B and PLGF-1 and -2 [22]. It has been approved by FDA for
he treatment of neovascular AMD  at the end of 2011, and for RVO
n 2012 [23]. The same molecular structure has been approved in
012 by FDA also for systemic use within the combination ther-
py for patients with metastatic colorectal cancer with the name of
iv-aﬂibercept. The two products present substantial differences
n both the preparation of the puriﬁed aﬂibercept and the drug
ormulation, indeed aﬂibercept/VEGF Trap-Eye undergoes more
uriﬁcation steps during manufacturing than ziv-aﬂibercept, and
t is formulated with proper buffers to minimize the risk of ocu-
ar irritation. The recommended regimen is an intravitreal dose
f 2 mg/month for three consecutive treatments, followed by one
njection every two months; a possible variant is represented by
imonthly injections from the beginning of the therapy [24].
Besides the just mentioned drugs, which are all proteins target-
ng pan-VEGF-A isoforms, there is another drug somehow unique
n its own way: pegaptanib, a 28-nucleotide RNA aptamer of ∼50
Da with a high selectivity for the VEGF-A165 isoform. Pegap-
anib sodium was registered for the treatment of neovascular
MD in 2004, representing the ﬁrst aptamer to enter in therapy.
ptamers can be envisioned as “chemical antibodies” since they
ffer the advantages of antibodies – high speciﬁcity and afﬁnity
 in a relatively small, chemically synthesized molecule without
ell-culture-derived contaminants. Moreover, aptamers are highly
ersatile and their commercial synthesis by large-scale manufac-
uring is fairly uncomplicated and cost-effective [25]. Pegaptanib is
sed off-label also for DME  and branch RVO (BRVO). The intravitreal
njection is at a dose of 0.3 mg  once every six weeks.
. The main target of anti-VEGF agents: VEGF165 among
ro-angiogenic and anti-angiogenic function—from one
ain actor to two  opponents
The human VEGF-A gene is organized in 8 exons separated by
 introns [26,27] resulting in the generation of at least 7 isoforms
f VEGF-Axxx, where xxx is the number of amino acids encoded.
he various isoforms contain between 121 and 206 amino acids,
here VEGF-A165 is the predominant member, followed by VEGF-
121 [28].
In recent years, great interest raised the discovery by Bates et al.
f the VEGF-A165b isoform, formed by an alternative splicing at
xon 8 of VEGF-A gene [29]. Now we know that the VEGF-A family
s composed by two subfamilies of splice variants which differ for
n alternative C-terminal sequence: the “conventional” VEGF-Axxx
or VEGF-Axxxa), formed by proximal splice-site selection, and the
novel” VEGF-Axxxb, generated by a splicing 66 bases downstream.
he alternative splicing of VEGF-A (since now referred as VEGF) thus
esults in proteins of the same length but with different amino acids
t the C-terminus: Cys-Asp-Lys-Pro-Arg-Arg in VEGFxxxa isoforms,
nd Ser-Leu-Thr-Arg-Lys-Asp in VEGFxxxb subfamily, respectively
29]. More importantly, the alternative splicing of exon 8 is the key
eterminant of isoform switching from “pro-angiogenic” VEGFxxxa
o “anti-angiogenic” VEGFxxxb.
All VEGF-A isoforms present the VEGFR-binding site and acti-
ate both Flt-1/VEGFR-1 and Kdr/VEGFR-2, although with different
fﬁnity and potency. VEGFR-1 mediates VEGF-induced chemo-
axis and inﬂammation, while VEGFR-2 is the main mediator of
he mitogenic, angiogenic and permeability-enhancing effects of
EGF [30,31]. In endothelial cells VEGFR-2 can be co-expressed
ith the neuropilin-1 (NRP1) co-receptor, which enhances VEGFesearch 103 (2016) 253–269 255
binding to VEGFR-2 and its signal transduction up to 6-fold [32]
(see also Fig. 1). NRP1 is an isoform-speciﬁc receptor for VEGF165a
[33]; VEGF165a binding to VEGFR-2 and NRP1 results in receptor
dimerization, rotation of its intracellular domain, and its autophos-
phorylation [34,35]. Conversely, this full rotation likely does not
occur when VEGF165b binds to VEGFR-2, resulting in an inefﬁcient
autophosphorylation of the receptor [33,34]. In respect to its angio-
genic counterpart, VEGF165b isoform is indeed a weaker agonist,
since it binds and poorly activates VEGFR-2, resulting in differ-
ential activation of intracellular pathways and, most relevantly,
not inducing vasculogenesis [34]. This feature seems to be due to
the difference in the C-terminal end of VEGF165b isoform. In fact,
VEGF165b does not bind to NRP1 [32,34], probably because its adja-
cent C-terminal sequence lacks Cys-160, which instead is present in
VEGF165a, affecting its secondary structure and folding, and likely
VEGFR-2 signaling [29]. It is possible that also the neutral charge
conferred by the two  terminal residues (Lys-Asp) of VEGF165b con-
tributes to the lack of interaction with NRP1 and the differential
VEGFR-2 downstream signaling [33].
4. Heterogeneous activities of the different VEGF isoforms:
a hot topic to understand the effects of selective and
non-selective VEGF inhibition
Since the beginning the predominant concept was that blocking
all the VEGF-A isoforms, instead of only VEGF165, was the winning
strategy to face neovascularization, therefore the most commonly
used anti-VEGF molecules injected for neovascular ocular diseases
have been ranibizumab and bevacizumab. More recent studies on
the role of the various VEGF isoforms and their biological effects,
as well as relevant clinical evidence raised in pharmacovigilance,
impose to reconsider previous ﬁndings on the molecular mecha-
nisms of anti-VEGF drugs in light of the advanced knowledge.
VEGF is secreted by several cell types in the retina, such as
vascular ECs, retinal pigment epithelium (RPE), pericytes, retinal
neurons, and astrocytes, indicating that VEGF plays important func-
tions in ocular homeostasis [36]. In particular, VEGF is a critical
factor for the homeostasis and plasticity of both blood vessels and
neurons.
4.1. The “conventional” VEGF isoforms and the vasculature
VEGF is essential for EC survival in normal conditions, and adult
blood vessels require autocrine VEGF for maintenance of homeo-
stasis [37]. In vivo treatment with a soluble receptor VEGF-Trap
in adult mice leads to early regression of normal blood capillar-
ies, in a sequence of events comprising cessation of blood ﬂow, EC
apoptosis, pericytes migration from regressing vessels to surviving
ones, and formation of acellular capillaries, also called basement
membrane ghosts [38]. The features of the various VEGF isoforms
and proteolytic products, their tissue expression and roles dur-
ing development and in adult, have been recently reviewed [39].
The speciﬁc functions of VEGF isoforms in vascular patterning
have been elucidated by transgenic mouse models. Mice selec-
tively expressing only VEGF164 present normal retinal vascular
development, while mice expressing only VEGF120 have severely
impaired outgrowth and patterning of developing retinal vessels
[40,41], indicating that VEGF164 plays the main role in vasculogene-
sis. However, VEGF164-deﬁcient mice expressing both VEGF120 and
VEGF188 showed no difference in physiological neovascularization
when compared with wild-type control animals, indicating that
other VEGF isoforms, in combination, may  compensate VEGF164
lack and be sufﬁcient to promote normal physiological neovascu-
larization [42]. From the development through all the life, the VEGF
isoforms act in concert to assure the optimal formation and main-
256 M. Amadio et al. / Pharmacological Research 103 (2016) 253–269
F 5 wor
w athwa
a activit
t
E
o
s
d
b
f
i
i
f
t
a
f
r
g
c
c
p
t
i
i
o
t
s
t
v
c
i
V
l
V
4
r
t
dig. 1. VEGF165 interacts with VEGFR-2 and neuropilin 1 in endothelial cells. VEGF16
ith  subsequent activation of tyrosine kinase domains and downstream signaling p
 disulﬁde bond between Cysteines 146 and 160 (in red color), necessary for VEGF 
enance of an adequately branched vessel network, guiding speciﬁc
Cs in growing and shaping the vascular tree [43–46]. Importantly,
f the total amount of VEGF secreted by RPE cells, 75% is repre-
ented by VEGF165 and 24% by VEGF121 [47]. The various isoforms
iffer not only for alternative splicing, as previously mentioned,
ut also for their distribution: for instance, VEGF121 is freely dif-
usible; VEGF188, which contains two heparin sulfate binding sites,
s sequestered by cell membrane or extracellular matrix; VEGF165
s in both soluble and bound status. Soluble isoforms are essential
or maintenance of RPE and choriocapillaries in the adult, indeed
he absence of both VEGF120 and VEGF164 in mice leads to an
ge-dependent degenerative phenotype characterized by RPE dys-
unction, loss of barrier properties, insoluble drusen-like deposits
esembling atrophic AMD  [48].
VEGF165 appears to be a critical isoform for retinal angio-
enesis not only under development but also in pathological
onditions; among the VEGF isoforms, VEGF165a is indeed the prin-
ipal mediator of inﬂammation and cellular immunity occurring in
athological retinal neovascularization, acting as a proinﬂamma-
ory cytokine targeting monocytes, macrophages and leukocytes,
n a positive feedback loop involving primarily ECs and sustain-
ng the neovascularization process [42,49]. The expression pattern
f VEGF isoforms, which is strictly regulated in normal condi-
ions, is disrupted in diseases; for example, in vivo it has been
hown that in pathological retinal neovascularization of rodents,
he VEGF164/VEGF120 ratio undergoes a ten-fold increase (∼25.5
ersus ∼2.2 in the physiologically developing retina), and this likely
ontributes to an angiogenic switch and to the appearance of
nﬂammation-associated vessel invasion within the vitreous [42].
EGF121 has less afﬁnity for VEGFRs than VEGF165, explaining the
ower mitogenic, proinﬂammatory potency of VEGF121 relative to
EGF165 [50,51].
.2. The “conventional” VEGF isoforms and the neuronsVEGF plays a fundamental role also in neurogenesis and neu-
oprotection, and VEGF abnormal expression has been linked
o several neurodegenerative disorders [52–54]. In vitro studies
emonstrated that VEGF, in particular the 165 isoform, increasesks as a dimer and its binding to VEGFR-2 promotes the dimerization of the receptor
ys ﬁnally leading to the effects reported in the colored circles. In VEGF165 is present
y and its interaction with neuropilin 1 (for more details see the text).
the survival of various types of neurons under different types
of stress via VEGFR-2 through multiple molecular mechanisms
including phospholipase C, PI3K, p38/MAPK and MEK1/2 activa-
tion, caspase-3 inhibition, and modulation of ion channel currents
[55–59]. Protective effects are also exerted on supporting cells, such
as astrocytes and microglia, through VEGFR-1 [60]. In vivo, intraoc-
ular injection of either VEGF120 or VEGF164 prevents retinal neuron
apoptosis resulting from ischemic/reperfusion (I/R) injury in the
rat, acting via VEGFR-2 signaling; however, the retina injected with
VEGF164 develops hemorrhages and edema that are not detected
after VEGF120 injection [61], suggesting that VEGF120/121 is more
implicated in the homeostasis of neurons and vessels than in
pathologic contexts. It is well known that downstream the VEGF
signaling is induction of Nitric Oxide Synthase (iNOS), leading to a
potent vasodilation [62], and that increasing volumetric blood ﬂow
enhances neuroprotection in ischemic tissues [63]; interestingly,
the authors showed that the VEGF120-mediated neuroprotection
in the I/R retina is only partially dependent by an increase of
iNOS and blood ﬂow, and that VEGF120 exerts a pro-survival action
also on retinal ganglion cells (RGCs) in vitro, strongly suggesting a
direct neuroprotective effect of VEGF120/121 [61]. In the same in vivo
model, a brief ischemic preconditioning increases both VEGF120 and
VEGF164 expression as a neuroprotective response, and this beneﬁc
pro-survival effect on RGCs is suppressed by either VEGFR-1/Fc
fusion protein or an anti-VEGF antibody; conversely and of great
interest, pegaptanib does not impair RGCs viability, further sug-
gesting that not fully abrogating VEGF responses, and especially
sparing VEGF120/121, represent a key strategy to preserve retinal
neurons [61]. More recently the same group conﬁrmed these ﬁnd-
ings in other in vitro and in vivo models on RGCs death, showing that
the pro-survival effects of VEGF120/121 are mediated by VEGFR-2
and PI3K/Akt signalings, and that total VEGF blockade signiﬁcantly
exacerbates neuronal cell death [64].
4.3. The emerging role of VEGF165b in blood vessels and neuronsAs mentioned, it has been discovered that VEGF family is actu-
ally constituted of two subfamilies, whose differential functions
still need to be fully investigated. It has been reported that in
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ormal conditions the “anti-angiogenic” VEGFxxxb isoforms repre-
ent the predominant proportion of the total VEGF in human eye
issues and ﬂuids; in particular, VEGF165b is highly expressed in
he normal eye (retina, lens, sclera, iris, vitreous) and it is down-
egulated in the vitreous ﬂuid of DR patients, where a switch in
EGF splicing from anti- to pro-angiogenic isoforms likely occurs
65]. This alteration in VEGF balance between the two  subfamilies
eems to be also present in other angiogenic-associated condi-
ions, as shown in oxygen-induced retinopathy (OIR) mouse model
nd in laser-induced choroidal neovascularization of AMD  mouse
odel [66,67]. In humans, beside in DR, signiﬁcantly lower lev-
ls of VEGF165b have been also revealed in the vitreous ﬂuid from
atients with RVO [68] but not with AMD, although a trend towards
 reduction (−20% VEGF165b median versus control subjects) was
etected [69]. Interestingly, in animal models of OIR and AMD,
ntraocular injections of recombinant human VEGF165b inhibit
etinal neovascularization [66,70,71]. To this regard, in vitro and
n vivo studies have demonstrated that VEGF165b inhibits several
EGF165a-induced processes, such as EC migration and prolifer-
tion, vasodilatation [29] and pathological angiogenesis in many
umor types [72,73]. And as, VEGF165b seems to be more than sim-
ly an anti-angiogenic factor, since in a dose dependent manner it
s able not only to inhibit the pathologic pre-retinal proliferation
f new vessels, but also to reduce the ischemic area in OIR ani-
al  model [70,71]. Speciﬁcally, these studies show that VEGF165b
avors physiological revascularization in vivo and acts as a survival
actor for both retinal endothelial and epithelial cells in vitro, these
atter effects being observed also with its sister isoform VEGF165a
71]. VEGF165b inhibits VEGF165a-induced EC migration and pro-
iferation but does not interfere with regrowth of blood vessels
ithin previously vascularized areas, a process named “revascu-
arization” [71,74], suggesting that VEGF165b contrasts the invasive
henotype and promotes physiological angiogenesis, in agreement
ith its weak agonist activity. Consistently, in a rat model of pro-
iferative retinopathy, VEGF164 blockade by EYE001/pegaptanib
nhibits pathological neovascularization but not physiological
evascularization, resembling the VEGF165b-mediated effects;
n contrast, a VEGFR-1/Fc chimera blocking all VEGF iso-
orms suppresses both pathological and physiological retinal
eovascularization [42].
In vitro and in vivo evidence also demonstrates that VEGF165b
s neurotrophic and exerts neuroprotective effects in response
o multiple insults in various types of neurons; in particular,
n vivo VEGF165b pretreatment protects RGCs and the inner nuclear
ayer cells in rat retinal I/R injury model [75]. As for VEGF165a,
EGF165b-mediated neuroprotection is through VEGFR-2, p44/42
APK activation, and caspase-3 inhibition, but, in contrast to
EGF165a, it does not involve either PI3K or p38 MAPK [75].
On the whole, these ﬁndings implicate that blocking all VEGF
soforms leads rapidly to an effective inhibition of ocular neovascu-
arization, but in the long term this may  result in detrimental effects
t both vascular and neuronal retinal level, mainly due to the loss
f the physiologic effects mediated by VEGF121 and VEGF165b. Local
nd systemic effects secondary to intraocular treatment with pan-
EGF drugs may  be also reinterpreted in light of these evidence, as
eported below.
. Developing the aptamer strategy to interfere with VEGF
The story of pegaptanib discovery and development started in
he 1990s, when precursors of pegaptanib were selected among
uge libraries of oligonucleotides, about 1014 RNA molecules
ontaining 30 randomized positions [76]. By using the SELEX
Systematic Evolution of Ligands by Exponential Enrichment) tech-
ology developed by Larry Gold’s group at the University ofesearch 103 (2016) 253–269 257
Colorado in the early 1990s [77], speciﬁc inhibitors of VEGF-A165
(from now referred as VEGF165) were searched. The pathogenic
role of VEGF165 in tumor vascularization and growth had been evi-
denced few years earlier [78–80]. The identiﬁcation of VEGF165 as
the main actor of pathological angiogenesis on one side and, on
the other, the concurrent research on aptamers as novel therapeu-
tics, converged to the development of some promising anti-VEGF
RNA ligands. For the initial selection of the anti-VEGF aptamers the
investigators used the recombinant human VEGF165 as a target [76].
The ﬁrst work on anti-VEGF aptamers, published in 1994,
reported an initial set of high afﬁnity RNA ligands selected for
their ability to inhibit the binding of [125I]VEGF to its recep-
tors in a concentration-dependent manner in human umbilical
vein endothelial cells (HUVECs) [76]. Competition experiments
on candidate anti-VEGF aptamers revealed that they all bound
to a similar site within the heparin-binding domain (HBD) of
VEGF165, and indeed they were displaced by heparin [76]. To
address the question of speciﬁcity of these high-afﬁnity ligands
towards VEGF165, the scientists performed binding experiments
with various heparin-binding proteins, such as PDGF (Platelet-
Derived Growth Factor) and FGF (Fibroblast Growth Factor). In
those years, speciﬁc inhibitors of VEGF, basically pan-VEGFs, were
limited to monoclonal antibodies [81] and soluble VEGF receptor
[82], thus the isolation of RNA molecules with unexpected binding
selectivity to VEGF165 aroused a great interest. The lead compounds
were further modiﬁed and optimized [83,84], t44-OMe having high
binding afﬁnity for VEGF165 and the best activity in the Miles assay,
an in vivo test to evaluate the capacity of a given substance to
inhibit vascular leakage following VEGF intradermal injection in
guinea pigs [84]. Interestingly, the addition of a 40 kDa polyethy-
lene glycol (PEG) to the 5′-end of the 27 nucleotides long t44-OMe
slightly decreased (about 4 fold) the binding afﬁnity to VEGF165,
but markedly improved the inhibitory activity in the Miles assay
(83% with PEG-conjugated t44-OMe; 48% with t44-OMe) [84]. The
more efﬁcient inhibition of VEGF-induced permeability displayed
by PEG-t44-OMe might be the consequence of a prolonged tis-
sue permanence of the aptamer due to its conjugation with PEG
[85]. Starting from PEG-t44-OMe, and few intermediates such as
NX1838 and EYE001, pegaptanib was ﬁnally generated [86,87].
Pegaptanib sodium is a covalent conjugate of 28 nucleotides in
length that terminates in a pentylamino linker, to which two  20 kDa
monomethoxy PEG units are attached via the two amino groups on
a lysine residue (Fig. 2). This drug represented the ﬁrst pharmaco-
logic approach joining the laser photocoagulation and verteporﬁn
photodynamic therapy, considered at that time the sole therapeutic
interventions for neovascular ocular diseases.
The literature on precursors of pegaptanib provides information
on their binding to VEGF, and it is thus useful to better understand
the molecular mechanism of inhibition of this aptamer and to clar-
ify its biological activity. Since the beginning it was evident that
the candidate aptamers under development were displaced from
VEGF165 by heparin, suggesting that the HBD of VEGF was involved
in the ligand-protein binding [76]. Accordingly, it was  then shown
that the amino acid sequence of VEGF that remained photo-cross-
linked to the aptamer after digestion corresponded to a speciﬁc
site within the HBD of VEGF165; more precisely, an uridine residue
within the minimal RNA sequence capable of high afﬁnity binding
to VEGF formed a cross-link with the residue cysteine-137 within
the exon 7-encoded domain of VEGF165, mediating much of the
heparin binding activity of VEGF [84]. These ﬁndings in vivo were
conﬁrmed, demonstrating that the uridine-14 of the therapeutic
aptamer forms a cross-link with cysteine-137 and that the HBD
is the primary determinant for the afﬁnity and speciﬁcity in the
complex formed by the aptamer and VEGF165 [88] (see also Fig. 2).
Notably, the HBD is completely lacking in the VEGF121 isoform.
258 M. Amadio et al. / Pharmacological R
Fig. 2. Primary and secondary structure of pegaptanib. The nucleotides are conju-
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. Sparing VEGF165b while targeting VEGF
The previously described differences in the C-terminal struc-
ures of VEGF may  also explain the fact that pegaptanib selectively
inds the angiogenic VEGF165a, likely sparing the anti-angiogenic
ounterpart, as better elucidated below. In other words, the C-
erminus of VEGF165a may  be the key determinant for both the
nteraction between HBD and NRP1, and the binding between
egaptanib and HBD. In agreement, NMR  data and three dimen-
ional solution structures of aptamer-ligand complexes reveal that
peciﬁcity and afﬁnity for a given binding site are profoundly inﬂu-
nced by the near residues, which affect the adaptive recognition
y the aptamer [89].
Interestingly, as later reported by the same group which ﬁrst
dentiﬁed [29] and characterized VEGF165b in terms of mecha-
ism of action and expression [74], pegaptanib does not bind to
EGF165b [71]. Speciﬁcally, to evaluate whether a direct interaction
etween pegaptanib and VEGF165b exists, the authors incubated
he RNA aptamer with VEGF165a or VEGF165b protein, separated
he samples on acrylamide gel under non-denaturating conditions,
nd probed the membranes with either an anti-VEGF165 antibody
etecting both VEGF isoforms, or a speciﬁc anti-VEGF165b anti-
ody directed to the nine C-terminal amino acids of VEGF165b [71],
hich is currently being used to detect this speciﬁc isoform in
uman tissues [90]. The blot showed a band shift of VEGF165a, but
ot VEGF165b, toward higher molecular weight when the aptamer
as added, suggesting that pegaptanib does not physically inter-
ct with VEGF165b [71]. The same authors reported that pegaptanib
nd VEGF165b given separately to human microvascular endothelial
ells (HMVECs) inhibit the VEGF165-induced cell migration; how-
ver, the concomitant treatment with the two inhibitors removes
he beneﬁt of each agent in the same assay, suggesting that,
lthough there is not a direct interaction between pegaptanib and
EGF165b, the combination of the two molecules does not add ben-
ﬁt [71]. This may  be explained considering that VEGF functions
s a dimer and, although till now it has been solely proven the
xistence of VEGF165/110 heterodimers [50], an alternative is that
EGF165b may  pair with VEGF165a reducing the angiogenic poten-
ial of the latter through a differential VEGFR signaling, and that
egaptanib may  interfere with the formation of this heterodimer.
owever, further studies are needed to clarify this point.esearch 103 (2016) 253–269
In contrast to pegaptanib, it has been shown that bevacizumab
binds to both VEGF165a and VEGF165b with equal afﬁnity [91], and
likely it is the same for ranibizumab, since it was designed on the
parent molecule bevacizumab. In vivo studies in a cancer model
report that VEGF165b strongly impairs the efﬁcacy of bevacizumab
and this fact implicates that patients expressing high levels of
VEGF165b may  be no-responders to bevacizumab and other pan-
VEGF drugs [91]. These ﬁndings may  also explain some of the
undesired side effects of pan-VEGF agents.
7. Gaining insight into pegaptanib mechanism of action
and its biological target
The differential biological effects, and related therapeutic pro-
ﬁle, exerted by pegaptanib in comparison with pan-VEGF drugs
mainly reside in the aptamer inhibitory activity selectively targeted
toward VEGF165—or we  may  even say the pro-angiogenic VEGF165a
isoform.
It has been suggested that pegaptanib, by binding to a site within
HBD, contrasts HBD interaction with NRP1 co-receptor and thus
only exerts an inhibitory effect on the NRP1-mediated ampliﬁca-
tion of VEGFR signaling, instead of an efﬁcient inhibition of the
VEGFR signaling itself [92]. In support of this hypothesis there is the
observations that VEGF121, which contains the receptor-binding
domain (RBD) but lacks the HBD and does not interact with NRP1,
activates both VEGFR-1 and VEGFR-2, although with much lower
potency than VEGF165 [50]. However, from the beginning, exper-
imental evidence showed that the pegaptanib precursor t44-OMe
efﬁciently blocked the binding of VEGF165 to both Flt-1/VEGFR-1
and Kdr/VEGFR-2 [84]. Accordingly, it was then clearly shown that
also the pegaptanib precursor NX1838 bound Kdr/VEGFR-2; in con-
trast, unambiguous data on VEGFR-1 were not produced because
of the lack of speciﬁc anti-Flt-1/VEGFR-1 antibodies at that time
[86]. Moreover, internal data Bausch & Lomb [referred by S. Giuf-
frida] support the assertion that pegaptanib can effectively inhibit
VEGF165 binding to its receptors, VEGFR-1 (IC50=0.47 nM), VEGFR-2
(IC50 = 1.10 nM), and NRP1 (IC50 = 0.23 nM). This report is based on
cell-free receptor plate binding studies and shows that the maximal
inhibition exerted by pegaptanib on VEGF165 binding to the differ-
ent VEGF receptors is 75–90% (the lowest for VEGFR-1; the highest
for VEGFR-2 and NRP1), suggesting subtle differences in the bind-
ing of VEGF165 to its receptors. To this regard, an hypothesis is that
the aptamer inhibits VEGFR signaling by providing a steric inter-
ference between RBD and the cell-surface receptors, as previously
evidenced for some anti-angiogenic HBD-binding proteins [88].
In vitro studies on HUVECs assessed that NX1838 inhib-
ited VEGF165 receptor binding and downstream signaling events,
including phosphorylation of VEGFR-2, phospholipase C activa-
tion, calcium mobilization, and cellular proliferation [86]. In this
report, the inhibition of VEGF165-mediated cellular events exerted
by NX1838 was comparable to that observed with an anti-VEGF
monoclonal antibody; in contrast, this aptamer was  ineffective
as an inhibitor of VEGF121-induced HUVECs proliferation [86].
NX1838 indeed did not bind VEGF121 isoform lacking HBD, site for
pegaptanib binding. Internal data from Bausch & Lomb [referred by
S. Giuffrida] report that pegaptanib binds VEGF189 with a lower but
signiﬁcant afﬁnity than VEGF165; we  cannot exclude that pegap-
tanib also binds exon 7-containing VEGF183 and VEGF206, which are
expressed at very low level and play a marginal role in angiogenesis.
Ranibizumab and bevacizumab bind to the RBD sequence
[15,93] which is common to all the VEGF isoforms, thus blocking the
binding of all of them to VEGFRs and the related angiogenic signal-
ing; this justiﬁes the more potent effect of these drugs in inhibiting
EC migration, proliferation and vascular permeability in compar-
ison to pegaptanib. On the other side, this strength of pan-VEGF
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rugs may  also represent their weakness, since such molecules
ounteract also the physiologic effects of VEGF121 and VEGF165b.
. Pegaptanib from biological target deﬁnition to current
herapeutic use
Preclinical in vitro and in vivo studies demonstrated that pegap-
anib precursors inhibit two main VEGF165-mediated functions, the
nhancement of EC proliferation and vascular permeability [84,86],
roviding the rationale for the therapeutic use of this aptamer
or pathologies characterized by angiogenesis and vascular leak-
ge. EYE001 (later on designated pegaptanib) was  tested in human
umor xenograft mouse model and in various animal models of
cular neovascularization, such as the Miles assay, the rat corneal
eoangiogenesis and the mouse retinopathy of prematurity mod-
ls, showing signiﬁcant attenuation of VEGF165-mediated effects
n eye diseases [87]. The open-label phase IA safety study on 15
atients with subfoveal choroidal neovascularization (CNV) sec-
ndary to AMD  revealed no signiﬁcant safety issues at 0.25–3 mg
oses of EYE001/pegaptanib, and that 80% of subjects showed
table or improved vision 3 months after a single intravitreous
njection [87], opening the way to larger clinical trials on patients
ith exudative AMD. Pegaptanib was then evaluated in two con-
urrent, multi-center, prospective, randomized, double-blinded,
ham-controlled, dose-ranging trials on patients with all types of
et AMD: the VEGF Inhibition Study in Ocular Neovascularization
VISION) trials. These studies showed that pegaptanib treatment
very 6 weeks reduced vision loss by about 50% in the ﬁrst year
nd maintained this beneﬁt stabilizing vision acuity at the second
ear [94,95]. In particular, the pooled analysis of these phase III
rials showed that 70% of patients treated with pegaptanib 0.3 mg
ersus 55% of patients receiving the sham injection lost fewer than
 lines of visual acuity on an Early Treatment Diabetic Retinopa-
hy Study (ETDRS)-style vision chart. Within the context of the
-year trial, an exploratory analysis at week 54 of vision outcomes
f a subgroup of naïve patients with early CNV secondary to AMD,
uggested that pegaptanib treatment is associated with enhanced
ision beneﬁts, likely due to increased preservation of photore-
eptors and/or RPE [96]. Analogously, the efﬁcacy of pegaptanib
s primary therapy for patients with early CNV-AMD was  evalu-
ted in a retrospective study with a mean follow-up of about 9
onths (range 6–14 months), which showed a 90% rate of improve-
ent or stabilization of vision outcomes for pegaptanib, beneﬁts
hat exceeded those reported in the VISION trial [97]. A retrospec-
ive study of patients with exudative AMD  with small lesion size
nd followed up over 1 year compared the effect of pegaptanib
ersus ranibizumab, concluding that the visual outcomes of the
wo drugs were equivalent [98]. However, after the approval of
an-VEGF inhibitors, these latter have been preferred, pegaptanib
onotherapy was reconsidered, and this drug was  evaluated as
 maintenance therapy following non-selective anti-VEGF agents
n wet AMD  [99]. To this regard, in a small number of patients
ith all types of wet AMD, induction therapy with bevacizumab
ollowed by pegaptanib maintenance produced visual acuity and
natomical improvements at 54-week [99]. The efﬁcacy and safety
f pegaptanib as a maintenance therapy was then assessed on a
arger scale with a phase IV, open-label, uncontrolled exploratory
tudy including patients with subfoveal wet AMD  [LEVEL study;
00]. The results showed that pegaptanib was safe and well tol-
rated, and that the visual acuity and anatomical improvements
ained during the induction phase were well preserved at 54-week,
ith only 50% of patients requiring a booster treatment given after
 mean of 5 months post-baseline. Similar results were reported
t 54-week for Japanese patients with neovascular AMD  enrolled
n the multi-center, prospective LEVEL-J study [101], and were fur-esearch 103 (2016) 253–269 259
ther conﬁrmed on a small subgroup of patients after a 3-year follow
up [102]. According to these ﬁndings, pegaptanib is presently used
mainly as a maintenance therapy following pan-VEGF agents in
long term treatment of wet AMD. Besides this indication, pegap-
tanib is used off-label for proliferative DR, DME, BRVO, and myopic
choroidal neovascularization [103–109].
9. Selective versus non-selective anti-VEGF drugs side
effects: an ongoing debate from the bench to the eye of
patients
Notably, non-selective anti-VEGF drugs, especially monoclonal
antibodies, obtained very good results in numerous clinical tri-
als (such as ANCHOR, CATT, IVAN, MARINA, HORIZON studies)
[110–115] to the extent that they are considered the most effective
therapies for neovascular eye diseases, but there is some concern
about their potential local and systemic side effects, especially
in the long-term period [as reviewed in 36]. Ideally, an effec-
tive and safe anti-VEGF therapy should reduce neovascularization
without damaging the normal vessels, and also preserving the
physiologic functions of the retinal neurons and other cells. As
mentioned, pan-VEGF agents exert a potent anti-angiogenic action
that exceeds the blockade of neoangiogenesis; for example, in vivo
studies showed that non-selective VEGF inhibition causes capil-
lary regression, robust and early changes in ECs, pericytes, and
basement membrane in the adult normal vasculature [116,117],
all effects likely due to the block of the physiological functions of
VEGF isoforms, besides the inhibition of the pathological effects, as
described in the previous paragraphs.
Local side effects are possible for theoretically every drug used
in ophthalmology, and include toxicity related to the substance
itself or due to the route of administration, such as in this case
to single or repeated intraocular injections. Among others, the
most common local adverse effects of anti-VEGF treatments com-
prise endophthalmitis, retinal detachment, intraocular pressure
increase, eye inﬂammation, hyperaemia and hemorrhage, which
can occur with major or minor incidence following treatment
with any of the anti-VEGF agents [for comprehensive reviews see:
118–120]. Instead, the main occurrence of some adverse effects
in non-selective anti-VEGF agents might be explained with their
indiscriminate inhibition of all VEGF isoforms, including VEGF121
and VEGF165b, which indeed seem to play a role mainly in physio-
logical processes at vascular and neuronal level.
9.1. Anti-VEGF drugs and atrophy of the retina
In both MARINA and ANCHOR trials on ranibizumab at 2 years,
the increase in RPE abnormalities was one of the most signiﬁcant
characteristic lesions associated to visual acuity loss [as reviewed in
121]. Analogously, the number of ranibizumab injections was sig-
niﬁcantly associated with the progression of RPE atrophy in wet
AMD  patients followed for a median of 16 months (range 3–36
months) [122]. It has been proposed that pan-VEGF blockade is
responsible of increasing geographic atrophy (GA) in AMD  patients,
a gradual complication characterized, among others, by choriocap-
illaries and RPE atrophy, photoreceptors death, and leading to a
progressive visual loss [123,124]. Monthly or PRN injection regi-
men with ranibizumab or bevacizumab led to development of GA
by 2 years in 18.3% of wet  AMD  subjects included in the CATT trials
[125]; an update of this study indicates that GA growth rate does
not differ between eyes treated monthly or PRN, but it may  be accel-
erated by ranibizumab [126]. Moreover, the multicenter cohort
SEVEN UP study assessing long-term outcomes 7–8 years after
initiation of intensive ranibizumab therapy in patients previously
enrolled in the MARINA, ANCHOR and HORIZON trials, evidenced
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hat, although ranibizumab is efﬁcacious in wet AMD, one third of
ubjects demonstrated visual beneﬁts and another third had poor
utcomes; more alarming, macular atrophy was detected by fun-
us autoﬂuorescence in 98% of all studied eyes, with the area of
trophy mainly localized in the fovea and signiﬁcantly correlated
ith a poor visual outcome [127]. Interestingly, to our knowledge
n literature there is only one report of rapid development of foveal
A possibly related to a single injection of pegaptanib in one patient
resenting an already imbalanced foveal choroidal circulation due
o AMD  complicated by chronic serous drusenoid pigment epithe-
ium detachment (PED) [128], suggesting that selectively inhibiting
EGF165 and preserving other isoforms may  avoid GA occurrence.
.2. Anti-VEGF drugs, RPE tears and other lesions
Other complications possibly occurring in wet  AMD patients
re ﬁbrosis and formation of scars; in addition, since the approval
f intravitreal pharmacotherapy, there has been a huge number
f reports of RPE tears developing after anti-VEGF injections, and
hus a debate raised whether in these cases anti-VEGF therapy
s beneﬁcial, or not, on the anatomical and visual outcomes. To
ite only a few of these evidence, RPE tears have been diagnosed
bout 2 months after the ﬁrst injection with an anti-VEGF agent,
nd observed in 12–15% of all eyes treated for PED in wet AMD
129]. The SEVEN UP study on ranibizumab reported the absence
f ﬁbrotic lesions in almost 40% of the examined eyes, although cen-
ral ﬁbrotic scars were demonstrated in approximately one third of
he retina, with signiﬁcant repercussions on visual acuity [127].
pproximately 45% of eyes treated with either ranibizumab or
evacizumab and enrolled in the CATT study developed scar by 2
ears [130]. However, the majority of these RPE tear cases identi-
ed after ranibizumab, bevacizumab or pegaptanib therapy were
ssociated with a pre-existing complication, a baseline vascular-
zed PED, which in most cases evolves into RPE tears [131,132]. A
ecent study with an average follow-up of 42 months in patients
ith a diagnosis of RPE tear developed spontaneously or after anti-
EGF therapy, stated that the formation of atrophic or ﬁbrotic
isciform scars occurred equally in both ranibizumab-treated and
iscontinued groups, and ﬁnally suggested that, in general, contin-
ing anti-VEGF therapy is beneﬁcial, reduces adverse outcomes and
mproves prognosis [133]. In support of this conclusion, in vitro and
n vivo studies showed that ﬁbroblast proliferation is stimulated
y VEGF and inhibited by administration of bevacizumab, which
ontrasts collagen deposition and improves the outcomes after
laucoma surgery [134]. It has been suggested that VEGF isoforms
lay distinct roles in scar formation, with VEGF189 being mainly
nvolved in ﬁbrosis; for this reason, pan-VEGF blockade may  have
 better anti-scarring potency than the selective VEGF165 inhibitor
egaptanib, which in vitro inhibits ﬁbroblast growth only at the
ighest doses tested, and whose beneﬁts in post-operatory seem to
e mediated mainly by inhibition of angiogenesis, but not reduction
f inﬂammation or collagen deposition [135].
.3. Anti-VEGF agents and the haemodynamics of eye vessels
Studies on the effects of anti-VEGF drugs on retrobulbar and
etinal haemodynamics in wet AMD  patients indicate that non-
elective molecules may  induce hypoperfusion. Speciﬁcally, 4
eeks after a single injection of bevacizumab, the ﬂow of all retrob-
lbar arteries—in particular the blood ﬂow velocities (BFVs) in the
entral retinal (CRA), temporal posterior ciliary (TPCA) and oph-
halmic arteries (OA) - has been shown to be reduced [136]. A
igniﬁcant vasoconstriction of the retinal arterioles lasting thirty
ays after each injection of ranibizumab was observed in wet  AMD
atients [137]. A more recent study showed that ranibizumab leads
o an early impairment of the native choroidal and retinal vascularesearch 103 (2016) 253–269
networks, but most of these effects are reversible after its discon-
tinuation; however, the study evidenced a signiﬁcant correlation
between the number of injections and percentage of changes in
BFVs of CRA at month 6 [138]. The sole study on pegaptanib, speciﬁ-
cally on DME  and BRVO patients, only shows a signiﬁcant decrease
of blood ﬂow velocity in the CRA after the third injection, possi-
bly due to a cumulative effect for repeated treatments; no effects
on retinal capillary blood ﬂow, velocity or resistance index in the
OA or TPCA have been evidenced in the small number of subjects
examined [139]. However, further and larger studies are needed to
conﬁrm that pegaptanib has a better proﬁle than other anti-VEGF
agents on the haemodynamics of retrobulbar and retinal vessels.
10. Risk of inhibiting VEGF beyond the eye
Since their appearance in clinics, many observational studies,
reviews and meta-analyses have been published on the systemic
tolerability of ophthalmic anti-VEGF drugs and related adverse
drug reactions (ADRs). Indeed, all the intraocular injected anti-
VEGF agents can pass through the blood-retinal barrier and enter
the systemic circulation, causing a decrease in VEGF plasma lev-
els at various degrees, with several consequences. For instance,
it was documented that intravitreous administered bevacizumab
rapidly penetrates the rabbit retina before leaking into the blood
circulation [140], and that in patients the intraocular injection of
bevacizumab strongly decreases the VEGF serum concentration, to
the extent that after 1 month after the antibody treatment blood
VEGF is still 23% of baseline [141]. The circulating VEGF protects
the vascular patency and integrity, and up-regulates NOS, thus
a prolonged anti-VEGF treatment potentially increases the risk
of hypertension and thromboembolic events [142]. Relevantly, in
comparison with healthy age- and sex-matched populations, neo-
vascular AMD  patients are elderly people presenting an increased
prevalence of hypertension, myocardial infarction, stroke, diabetes,
and thus they may  be more susceptible to cardiovascular and cere-
brovascular toxicities and prone to manifest ADRs [143–147]. In
particular, the most frequently documented comorbidities with
wet AMD  are hypertension and other cardiovascular diseases,
accounting 57.5% of cases [148]. After a 10-year period, people
with early-stage AMD  have almost a 2-fold cumulative incidence of
stroke than controls (4.08% versus 2.14%) [149]. As well, DR subjects
are more likely to have an increased risk for vascular events [147].
A recent review of some relevant clinical trials shows that the
rates of serious thromboembolic events, such as stroke, heart attack
and death, are similar for AMD  patients treated with different anti-
VEGF agents. In particular, the authors state that in these subjects
the arterial thrombotic risk appears sufﬁciently low, when com-
pared with the natural incidence of thromboembolic events in this
category of elderly people, to be considered acceptable and coun-
terbalanced by the advantage of a visual improvement [150]; in few
words, the risk of thrombotic events is seen as the worthy price for
ocular beneﬁts. Similarly, a recent meta-analysis in DME  patients
evidences no signiﬁcant difference between anti-VEGF treated sub-
jects and controls for arterial thromboembolic events; however, the
authors judge the quality of the evidence on these ADRs as moder-
ate due to an incomplete report of safety data, and the exclusion of
high-risk participants (people with previous cardiovascular events)
in some studies [108]. Another systematic review of pre- and post-
marketing safety data on ranibizumab, pegaptanib and aﬂibercept,
including 7720 spontaneous reports from the European database
EudraVigilance, highlights an increased number of thromboem-
bolic events (0.8–5%) and mortality (2.8–4%) with anti-VEGF agents
evidenced by post-marketing studies, and suggests the need to
properly evaluate the risk for such serious and long-term ADRs with
further studies [120]. Again, data from real life evidence relevant
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afety issues for some non-selective anti-VEGF agents; a compar-
tive analysis of ADRs in the WHO  database shows an elevated
isproportionality for cardiovascular events in patients treated
ith ranibizumab, in particular myocardial infarction, congestive
eart failure, and cerebrovascular accidents [119]. This analysis
as performed on 3180 reports of worldwide pharmacovigilance
rom 2002 to 2012, corresponding to 7753 drug-reaction pairs con-
erning ranibizumab (5130, 66%), bevacizumab (2069, 27%), and
egaptanib (554, 7%). Interestingly, although the number of reports
n pegaptanib were more limited in comparison with other agents,
o relevant safety issues were identiﬁed for this drug. In agree-
ent, safety data from year 2 and 4 of the VISION trial previously
uggested no evidence of an increased risk of systemic adverse
vents associated with long-term treatment with pegaptanib [151].
s AMD  patients, DR population may  require long-term anti-VEGF
herapy, thus it is important to consider potential systemic effects
n subgroups prone to vascular events when deciding between non-
elective and selective agents [152]. In light of this consideration,
nd being pegaptanib potentially safer than non-selective anti-
EGF agents, some authors have suggested to use pegaptanib as
n initial therapy for DME, substituted with a pan-VEGF blocker in
ase the desired result is not achieved [153].
VEGF regulates vascular permeability in various districts and
t exerts neurotrophic and neuroprotective effects on blood-retinal
nd blood-brain barriers [154], thus it is conceivable that pan-VEGF
uppression induced by intravitreal treatment may be deleterious
lso at cerebral level. According to the above mentioned sponta-
eous reports from the WHO  database, a potential increased risk
f cerebrovascular events associated with ranibizumab, especially
ith a more intensive treatment, was evidenced also by meta-
nalyses on ﬁve clinical trials with this drug (FOCUS, MARINA,
NCHOR, PIER, and SAILOR) [155,156].
Clinical and experimental ﬁndings report that the use of anti-
EGF agents can result in neuronal damage, often leading to
ain [157]. Recent evidence have shown that both VEGF165a
nd VEGF165b are neuroprotective, but they have pro- and anti-
ociceptive effects, respectively [158]; the authors thus suggest
hat pain associated with anti-VEGF agents, and especially with
olecules non-discriminating among the two 165 isoforms, is not
ully attributable to a loss of a neuroprotective effect, but possibly
lso involves the modulation of nociception by VEGF-A isoforms.
Another organ dependent on VEGF and potentially exposed to
njury from systemic absorption of ophthalmic anti-VEGF drugs
s the kidney. Hypertension and proteinuria have been described
uite soon as adverse effects of systemic treatment with beva-
izumab [159]. In general, anti-VEGF agents have common adverse
ascular effects attributable directly or indirectly to VEGF blockade,
ncluding hypertension and renal vascular injury, usually mani-
ested by proteinuria and thrombotic microangiopathy [160]. The
enal toxicity is likely due to the loss of VEGF functions in the devel-
ped kidney, and to the close relationships existing among VEGF,
O, endothelin-1 and angiotensin-II expression [161]. In partic-
lar, VEGF121 is fundamental for renal function [162] and it has
een shown to protect rats from kidney infarction in thrombotic
icroangiopathy through maintaining NO production and/or pre-
enting EC death [163]. Down-regulation of NO by anti-VEGF has
een also implicated among the mechanisms underlying hyper-
ension, besides rarefaction of the microvasculature induced by
nti-VEGF agents [164].
Further studies are needed to better identify the main throm-
oembolic events related to the use of anti-VEGF agents, in
articular non-selective inhibitors, and their occurrence. However,
he risk for some systemic ADRs may  be increased in patients
reated with anti-VEGF agents due to their intrinsic characteris-
ics; moreover, since most of the patients are aged 65 or older,
ge-related physiologic changes, such as impairment of hepaticesearch 103 (2016) 253–269 261
and renal function, may  increase the odds for ADRs. To this crit-
icism we  should add potential comorbidities and polypharmacy,
which are common in the elderly and contribute to increase risk
factors for cardio- and cerebro-vascular events. In light of these
evidence, pegaptanib maintenance strategy after a loading phase
with pan-VEGF drugs may  represent a safer therapeutic option in
AMD  patients with various comorbidities, offering clinically mean-
ingful beneﬁts with a minimal systemic exposure to non-selective
VEGF inhibition (and related potential side effects), reduced num-
ber of intravitreal injections required for treatment, and thus an
improved cost/effectiveness proﬁle [165].
11. Tachyphylaxis: a relevant issue in anti-VEGF therapy
Anti-VEGF therapy is efﬁcacious in the majority of patients;
however, in the long-term, repeated intravitreal injections of these
molecules seem to be associated with a reduced efﬁcacy. To this
regard, still up to one-fourth of all treated patients, deﬁned as
no-responders, does not beneﬁt from intravitreal injections and
visual acuity deteriorates even under treatment [166]. In general,
long-term efﬁcacy of a drug can be affected by tachyphylaxis, a phe-
nomenon which is often confused with tolerance, both determining
a reduced drug efﬁcacy. When drugs are administered repeatedly
over a short period, tachyphylaxis can develop quite quickly and
no response is observed following a dosage increase, although the
efﬁcacy can be restored if the compound is suspended for a short
while [167].
Keane and collaborators [168] ﬁrst speculated the possible
implication of the tachyphylaxis phenomenon following adminis-
tration of ranibizumab for the treatment of neovascular AMD, and
a diminished therapeutic response due to tachyphylaxis was also
indicated for intravitreal bevacizumab [169,170].
Although some cases of presumed tachyphylaxis may  be
ascribed to a poor or suboptimal response to treatment [11], several
mechanisms have been proposed to contribute to the diminished
drug response, such as the alteration of the neovascular mem-
brane including increased ﬁbrosis, chronic changes in the vessel
wall and in relevant neighboring structures as photoreceptors or
RPE [167]. The attenuated response after repeated administration
may  be also explained in terms of a raise in other angiogenic signal-
ing pathways which are aimed to compensate the blocked activity
of VEGF; for example, macrophages located within the choroidal
neovascular tissue may  respond to VEGF inhibition by upregulat-
ing the production of VEGF itself [170]. As already reported for
other therapeutic humanized monoclonal antibodies, the forma-
tion of circulating neutralizing antibodies may  also take part to
tachyphylaxis; indeed, neutralizing antibodies have been already
documented against ranibizumab [171] and bevacizumab [172].
Clearly, this last aspect is in favor of pegaptanib since aptamers
are nonimmunogenic and are less likely to cause tolerability issues
[88]. Genetic variants of the VEGF gene seem also to alter the
response to anti-VEGF treatment [173]; therefore, it has been sug-
gested that even minor differences in the binding properties might
explain a differential response to the various anti-VEGF thera-
peutics, offering the possibility of a response even in patients
who developed a tolerance to one drug [166]. Within this gen-
eral context, clinical evidence demonstrated that no-responders to
either bevacizumab or ranibizumab beneﬁt from a switch to the
other drug [166,174,175]. Moreover, a signiﬁcant improvement in
visual and anatomical outcomes was also described after switch-
ing therapy to aﬂibercept in 34 eyes with persistent subfoveal ﬂuid
formerly treated with ranibizumab [176]. More recently, switch-
ing to pegaptanib monotherapy has been also documented to be
strongly effective in those AMD  patients who did not respond to
ranibizumab or ranibizumab combined with photodynamic ther-
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py [177]. The authors ascribe the efﬁcacy of pegaptanib mainly
o its selectivity towards the VEGF165 isoform and to the fact that
t is immunologically lenient. Moreover, since according to Pﬁzer’s
nternal data pegaptanib has a weak binding ability towards PDGF,
hey also assert that this feature can additionally contribute to
egaptanib activity [177]. To this regard, several lines of evidence
uggest that the response of blood vessels to anti-VEGF therapy
s inﬂuenced by vessel maturation which involves pericytes [see
ef. 178]. The recruitment of pericytes on endothelial cells is medi-
ted by PDGF-B signaling via PDGF receptor-type  (PDGFR-).
ndeed, transgenic mice lacking PDGF-B and PDGFR- are charac-
erized by abnormal vessel stabilization and maturation [179], and
nhibition of PDGF cascade increases EC sensitivity to anti-VEGF
gents [180]. Therefore, a combined therapy targeting PDGF-B and
EGF-A may  represent a more effective pharmacological approach
o face neovascular AMD and possibly to avoid tachyphylaxis chal-
enge. Within this context, pegaptanib itself, although provided
ith a weak binding activity towards PDGF, may  further beneﬁt
f this combination therapy strategy not only in inhibiting new
essel growth but also vessel regression, as documented by Jo and
ollaborators in mice [178].
2. Future perspectives in eye neovascularization:
ligonucleotide-based interventions to modulate VEGF
athway
Anti-VEGF therapy has certainly represented a breakthrough
ntervention to counteract pathological angiogenesis, although it
hould be taken into account that these agents usually help to
elay further vision loss rather than to improve it. This latter aspect
nderscores the need to identify novel approaches, also considering
hat novel VEGF-dependent [181,182] as well VEGF-independent
athways [183,184] may  be involved, the latter possibly contribut-
ng to better explain the resistance, observed in some patients, to
he anti-VEGF treatment itself.
Within this general context, as recently reviewed [185], efforts
ave also been directed to develop advanced drug-delivery devices
o reduce treatment burden, such as using the encapsulated
ell technology (designed to deliver active compounds directly
nto the vitreous following trans-scleral implantation) or utilizing
olloidal drug carriers (consisting of suspensions of microparti-
les/nanoparticles or liposomes), and also taking into account the
eed to develop eye drop or oral formulations to improve patient
ompliance. Moreover, considering that, as recently reviewed
185–187], single nucleotide polymorphisms can play a predictive
ole in AMD  progression or, in general, in the response to treat-
ent, pharmacogenomics studies may  help in the choice of a more
ppropriate therapy.
The present paragraph speciﬁcally deals with novel
ligonucleotide-based interventions in the eye mainly target-
ng, directly or indirectly, VEGF mRNA/protein/receptors or to be
sed in combination with the currently used anti-VEGF agents
Table 1; Fig. 3), leaving the reader to other recent publications for
ifferential pharmacological approaches or biological targets [i.e.
3,24,180,188].
2.1. Small interfering RNAs (siRNAs)
Sometimes also named short interfering RNAs or silencing RNAs,
iRNAs are double-stranded RNA molecules, 20–25 base pairs in
ength, capable of operating gene silencing at posttranscriptional
evel. Indeed, their catalytic nature allows for one siRNA to guide the
leavage of thousands of mRNAs, resulting in effective gene silenc-
ng with no translation of the related proteins. These molecules holdesearch 103 (2016) 253–269
a great potential since can be easily designed and are characterized
by high efﬁcacy and speciﬁcity [189].
Bevasiranib (OPKO Ophthalmologics) is a double-stranded RNA
of 21 nucleotides in length directed to VEGF-A mRNA. In particu-
lar, the primary sequence of one strand of bevasiranib [reported
by Dejneka et al. 190] has 100% homology to 21 nucleotides within
the exon 4 of VEGF-A present in all the VEGF-A isoforms. Preclinical
studies documented bevasiranib efﬁcacy in inhibiting neovascu-
larization in both mice and nonhuman primate models [191,192].
Moreover, in rabbits, an extensive uptake into the retina was
observed following intravitreal injections of a single dose of either
0.5 mg/eye or 2.0 mg/eye of 3H-bevasiranib [193]. Promising results
for the treatment of AMD  and DME  originated from Phase I and II
clinical trials, also showing that bevasiranib effects were not man-
ifest until 6 weeks after treatment. However, in March 2009 OPKO
Health Pharmaceuticals decided to terminate its Phase III clinical
study for the treatment of wet  AMD.
Sirna-027 (also named AGN211745; Allergan) is a chemical-
modiﬁed siRNA that targets a conserved region of VEGFR-1 mRNA.
In mice, it was shown to reduce pathological angiogenesis in a
laser-induced CNV model [194], and it was proven to be safe and
effective in nonclinical safety studies [195]. Based on its preclinical
activity and tolerability, a Phase I study was  subsequently con-
ducted concluding that a single intravitreal dose of Sirna-027, up
to 1600 g/eye, is well tolerated in patients with CNV resulting
from neovascular AMD  [195]. However, no additional trials are cur-
rently running on this molecule (search up to July 16th 2015 at:
ClinicalTrials.gov and EU Clinical Trials Register).
PF-04523655 (developed by Quark Pharmaceuticals and now
licensed to Pﬁzer) is a 19-nucleotide, O-methyl stabilized, siRNA
that speciﬁcally targets the DNA-damage-inducible transcript 4
(DDIT4) genes, also known as REDD1 or RTP-801, indirectly
leading to a decrease in VEGF-A production [24]. RTP801 is a
hypoxia-inducible factor 1–responsive gene, which displays strong
hypoxia-dependent up-regulation both in vitro and in vivo. Indeed,
in diabetic rats its expression usually increases by up to 70% in
RPE/choroid and it is reduced by the administration of PF-04523655
[196]. Furthermore, RTP801 knockout mice show a signiﬁcant
reduction in retinal neovascularization in a model of retinopathy
of prematurity [197]. A Phase I multicentre study has been com-
pleted on AMD  in 2010, showing that a single intravitreal injection
of 50–3000 g of PF-045237655 is generally safe and well toler-
ated over 24 months [198]. A Phase II interventional clinical trial
(the DEGAS study) was subsequently conducted to evaluate the
safety and efﬁcacy of three doses of PF-04523655 (0.4 mg,  1 mg
and 3 mg)  for the treatment of DME  in comparison with focal/grid
laser. In general, PF-04523655 was  proven to be safe and well-
tolerated, with few adverse events judged treatment-dependent.
All the three dose levels of the siRNA continued to improve visual
acuity from baseline through month 12 in patients with DME. More-
over, at month 12, a trend for a greater improvement in visual acuity
from baseline was  observed in the 3 mg  PF-04523655 group with
respect to the laser photocoagulation one. Unfortunately, the study
was terminated early at month 12 based on the high patient dis-
continuation rate, mainly due to lack of efﬁcacy [199]. Two Phase II
studies have been additionally run to investigate the beneﬁts of a
combined therapy of this siRNA with ranibizumab in wet AMD  and
in DME, respectively. The ﬁrst clinical trial, the MONET study, which
assessed the efﬁcacy of different dosing paradigms of PF-04523655
versus ranibizumab (0.5 mg) showed that, in subjects with neovas-
cular AMD, the combined therapy leads to an average gain in visual
acuity that is more elevated than with ranibizumab monother-
apy, with no safety concerns identiﬁed [200]. In relation to the
second clinical trial, the dose escalation study and evaluation of
PF-04523655 with/without ranibizumab (MATISSE study) carried
in DME  patients, although already completed, no results have been
M. Amadio et al. / Pharmacological Research 103 (2016) 253–269 263
Table  1
Current drugs and novel oligonucleotide-based molecules to face ocular neovascularization. The drugs currently used (also off-label) in therapy or the oligonucleotide-based
molecules under clinical trials and potentially useful to counteract ocular neovascularization in different eye diseases are reported. When not speciﬁcally indicated, the
biological target is referred to the protein (for more details see text, paragraph 12). PLGF: placental growth factor.
Name Type of molecule Biological target Clinical stage Company marketing/developing
the agent
RANIBIZUMAB Recombinant
humanized
monoclonal antibody
fragment
All VEGF-A isoforms Current drugs Novartis
BEVACIZUMAB Recombinant
humanized
monoclonal antibody
Roche
AFLIBERCEPT Fusion protein All VEGF-A & VEGF-B isoforms + PLGF Bayer
PEGAPTANIB RNA aptamer VEGF-A165 only Bausch & Lomb
BEVASIRANIB siRNA VEGF-A mRNA Phase III OPKO Ophthalmologics
SIRNA-027 siRNA VEGFR-1 mRNA Phase I Allergan
PF-04523655 siRNA DDIT4 mRNA Phase II Developed by Quark
Pharmaceuticals, now licensed to
Pﬁzer
ALN-VSP02 Dual -siRNA VEGF-A and KSP mRNAs Phase I Alnylam Pharmaceuticals
E10030 DNA aptamer PDGF-BB Phase III Ophthotech
ARC1905 RNA aptamer C5 complement Phase I Ophthotech
Fig. 3. Oligonucleotide-based interventions targeting VEGF and other molecules involved in neovascularization. Left panel: schematical representation of the retinal layers,
vasculature, and some of the cell types producing VEGF (e.g. retinal pigment epithelial cells, glial cells, endothelial cells). Secreted VEGF is depicted as a yellow dot. Right
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osted thus far (search up to July 16th 2015 at: ClinicalTrials.gov
nd EU Clinical Trials Register).
Although no speciﬁc studies have been yet performed on ocular
iseases, it is worth to mention ALN-VSP02 (Alnylam Pharma-
euticals) since it is a lipid nanoparticle-formulated dual-targets
rug candidate. It contains two different siRNAs, chemically mod-
ﬁed (with 2′-O-methyl groups to minimize immunostimulation)
n a 1:1 molar ratio, directed to two different pathways: VEGF-A
nd kinesin spindle protein (KSP). KSP is a member of the kinesin
uperfamily of microtubule-based motor proteins whose inhibi-
ion determines cycle arrest at mitosis, ﬁnally leading to cell death
201]. To assess the activity and safety of intravenous ALN-VSP02 in
umans, a Phase I trial was initiated in patients with advanced solid
umors with liver involvement. On the whole, ALN-VSP02 was  well
olerated, with an adverse event proﬁle favorable in comparison
ith chemotherapy and with other orally or intravenously targeted
herapies administered in oncology. At molecular level, ALN-VSP02es: endothelial cells and pericytes. Aptamers (in green color), siRNAs (in blue color)
ombination with the current anti-VEGF agents (for more details see text, paragraph
counteracts the translation of both VEGF-A and KSP proteins, lead-
ing to growth inhibition of tumor cells and complete regression of
liver metastases in endometrial cancer [202].
No Phase II clinical trials are currently running (search up to July
16th 2015 at: ClinicalTrials.gov and EU Clinical Trials Register).
12.2. Aptamers
Aptamers represent a step forward with respect to siRNAs;
indeed, although still oligonucleotide-based molecules, they do not
necessarily require transfection and their stability/bioavailability
can be largely improved since the in vitro production allows to
manipulate their kinetic properties. In particular, 2′F or 2′OMe
modiﬁcations as well as the presence of conformationally restricted
nucleotides confer resistance to nucleases, while PEG-conjugation
limits renal ﬁltration [188].
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As previously said, pegaptanib has been the ﬁrst aptamer
ntered in therapy. Besides pegaptanib, later on other aptamers
ave been synthesized to target VEGF. For example Nonaka and
ollaborators identiﬁed a DNA aptamer (named Vap7) able to bind
oth VEGF121 and VEGF165 isoforms through the RBD region. How-
ver, they subsequently optimized this aptamer for a diagnostic
otential application as biosensor for VEGF detection [203,204].
As cited earlier, current theories suggest that blocking simul-
aneously VEGF-A and PDGF results in a more effective inhibition
f neovascularization [178,205]. PDGF is a family of proteins com-
rising four different polypeptides (PDGF A–D) which can combine
ither as homodimers or heterodimers. The homodimer PDGF-BB
as been involved in pericyte recruitment, maturation and survival
hrough the binding on its speciﬁc receptor, namely the PDGFR-,
n pericytes [206]. Indeed, PDGF inhibition causes a loss of peri-
ytes, leaving ECs vulnerable to anti-VEGF therapy, an effect that
an also help avoiding tachyphylaxis.
On these premises it has been designed E10030 (initially
eveloped by NexStar Pharmaceuticals and subsequently by Oph-
hotech), a DNA aptamer speciﬁcally targeting PDGF-BB. This drug
andidate is a PEGylated, 2′F- and 2′OMe-modiﬁed aptamer of
9 nucleotides. E10030 has been successfully assessed in associa-
ion with anti-VEGF molecules in inducing neovascular regression
207]. A Phase I trial was performed to determine the combined
ffect of E10030 and ranibizumab on subjects with subfoveal CNV,
howing a signiﬁcant vascular regression and a superior efﬁcacy in
omparison to ranibizumab monotherapy after 12 weeks of treat-
ent [208]. Similar results have been obtained in a Phase II trial
here a greater efﬁcacy was observed, following 6 monthly injec-
ions, especially with the higher dose of E10030 in combination
ith ranimizumab with respect to ranibizumab alone [189]. Phase
II studies are currently running/recruiting to evaluate the safety
nd efﬁcacy of E10030 in combination with ranibizumab or beva-
izumab or aﬂibercept in comparison to the respective anti-VEGF
lone (search up to July 16th 2015 at: ClinicalTrials.gov and EU
linical Trials Register).
Still remaining in the context of combined therapies, another
romising aptamer to be associated to anti-VEGF agents is ARC1905
Ophthotech Corp.) which targets C5 complement. C5 is a serum
lycoprotein that is cleaved in two fragments, C5a (active) and
5b, during complement activation. C5a is chemotactic and plays
 key role in stimulating neutrophil-endothelial adhesion [209].
he aptamer antagonizes C5 cleavage thus preventing complement
ctivation. A Phase I trial has been completed on the safety, toler-
bility, and pharmacokinetic proﬁle of multiple doses of ARC1905
n combination with ranibizumab in subjects with subfoveal CNV
econdary to AMD, however up to now no results have been posted
search up to July 12th 2015 at: ClinicalTrials.gov and EU Clinical
rials Register).
3. Conclusions
The study of anti-VEGF strategies in the treatment of ocular dis-
ases linked to abnormal vascularization raises several questions
elevant for both the understanding of the biology of the VEGF
ystem and the rational design of the interventions directed to
ounteract VEGF. The observations on the role of VEGF in AMD
nd DR also underscore the need to increase the knowledge of the
olecular bases of ocular diseases due to an impaired angiogenesis
ontrol.
The discovery of several isoforms of VEGF having different bio-ogical activity has revealed a previously unforeseen biological
omplexity which needs to be addressed when studying the clinical
ctivity of currently available anti-VEGF drugs and while explor-
ng new molecules active on this target. In particular, an answeresearch 103 (2016) 253–269
has to be provided to the question whether for a full antiangio-
genic activity is better to act against all the existing VEGF isoforms
or to selectively block few or one of them. The fact that some of
the VEGF isoforms have antiangiogenic and neuroprotective action
suggests that the VEGF system is physiologically balanced and that
in presence of an angiogenic process it would be preferable, in the
long run, to hit the angiogenic isoforms, leaving unaffected those
isoforms having a different biological activity, the neutralization of
which may  be responsible for a derangement of vasculature control
as well as of tissue reparative processes. When matching the molec-
ular proﬁles and comparing the clinical activities of the available
drugs, in particular of the pan-VEGF antibodies and of the aptamers,
such as pegaptanib, displaying a preferential afﬁnity toward the
VEGF165a isoform, one is tempted to speculate that a selective
action is sufﬁcient to sustain in the time the antiangiogenic effect,
while to quickly develop a full block of the angiogenic process, an
action directed toward all the isoforms is more effective. The pre-
clinical studies with some of the newer and more selective siRNAs
will help to clarify this point. In the meantime, the new molecular
advances may  be used to better tailor the existing therapies and
to explain some of the cases of therapy-resistant patients and to
understand the possible mechanisms underlying their side effects.
The discovery that, in addition to VEGF, other factors, such as PDGF,
may participate to the control of the angiogenic process, raises
another question: whether it is necessary to simultaneously act also
on these other molecules to optimize therapy and/or avoid tachy-
phylaxis. On the other hand it is possible that different patients,
so far included in the same diagnostic category, indeed have dif-
ferent molecular dysfunctions underlying their disease requiring a
more reﬁned proﬁling of the VEGF isoforms and of the other factors
regulating angiogenesis in that particular patient/disease.
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